Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

• Status: Completed
• Trial end date: 2017-03-19

Summary

Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the course of this study, it will be evaluated whether a particular type of blood cell, called a cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation. CIK cells are present in small quantities in the bloodstream but their numbers can be expanded after a brief period of nurturing in a laboratory.

• Phase: Phase 2

Details

• Lead Sponsor: Everett Meyer
• Treatments: Antilymphocyte Serum; Cyclosporine; Cyclosporins; Mycophenolate mofetil; Mycophenolic Acid; Thymoglobulin